Yajun Zhang1, Pei Wang2, Tengjiao Wang3, Yuan Fang2,4, Yongmei Ding1, Qijun Qian5,6,7,8. 1. Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital, Navy Medical University, Shanghai, 201805, China. 2. Shanghai Engineering Research Center for Cell Therapy, Shanghai, 201805, China. 3. Department of Bioinformatics, Institute of Translational Medicine, Navy Medical University, Shanghai, 201805, China. 4. College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, 310018, Zhejiang, China. 5. Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital, Navy Medical University, Shanghai, 201805, China. qian@shcell.org. 6. Shanghai Engineering Research Center for Cell Therapy, Shanghai, 201805, China. qian@shcell.org. 7. Department of Medical Oncology, Shanghai Mengchao Cancer Hospital, Shanghai, 201805, China. qian@shcell.org. 8. Shanghai University Cell Therapy Innovation Research Institute, Shanghai, 201805, China. qian@shcell.org.
Abstract
BACKGROUND: Although chimeric antigen receptor (CAR)-T cell therapy has been remarkably successful for haematological malignancies, its efficacy against solid tumors is limited. The combination of CAR-T cell therapy with immune checkpoint inhibitors (CPIs), such as PD-1, PD-L1, and CTLA-4 antibodies, is a promising strategy for enhancing the antitumor efficacy of CAR-T cells. However, because most patients acquire resistance to CPIs, investigating other strategies is necessary to further improve the antitumor efficacy of CAR-T cell therapy for solid tumors. Recently, CD40 agonist antibodies showed potential antitumor efficacy by activating the CD40 pathway. RESULTS: Based on the piggyBac transposon system, rather than the widely used viral vectors, we constructed a meso3-CD40 CAR-T targeting region III of mesothelin (MSLN) that possessed the ability to secrete anti-CD40 antibodies. Compared with meso3 CAR-T cells, which did not secrete the anti-CD40 antibody, meso3-CD40 CAR-T cells secreted more cytokines and had a relatively higher proportion of central memory T (TCM) cells after stimulation by the target antigen. In addition, compared with meso3 CAR-T cells, meso3-CD40 CAR-T cells had a more powerful cytotoxic effect on target cells at a relatively low effector-to-target ratio. More importantly, we demonstrated that the antitumor activity of meso3-CD40 CAR-T cells was enhanced in a human ovarian cancer xenograft model in vivo. CONCLUSIONS: In conclusion, these results highlight anti-CD40-secreting CAR-T cells generated by nonviral vectors as a potential clinical strategy for improving the efficacy of CAR-T cell therapies.
BACKGROUND: Although chimeric antigen receptor (CAR)-T cell therapy has been remarkably successful for haematological malignancies, its efficacy against solid tumors is limited. The combination of CAR-T cell therapy with immune checkpoint inhibitors (CPIs), such as PD-1, PD-L1, and CTLA-4 antibodies, is a promising strategy for enhancing the antitumor efficacy of CAR-T cells. However, because most patients acquire resistance to CPIs, investigating other strategies is necessary to further improve the antitumor efficacy of CAR-T cell therapy for solid tumors. Recently, CD40 agonist antibodies showed potential antitumor efficacy by activating the CD40 pathway. RESULTS: Based on the piggyBac transposon system, rather than the widely used viral vectors, we constructed a meso3-CD40CAR-T targeting region III of mesothelin (MSLN) that possessed the ability to secrete anti-CD40 antibodies. Compared with meso3CAR-T cells, which did not secrete the anti-CD40 antibody, meso3-CD40CAR-T cells secreted more cytokines and had a relatively higher proportion of central memory T (TCM) cells after stimulation by the target antigen. In addition, compared with meso3CAR-T cells, meso3-CD40CAR-T cells had a more powerful cytotoxic effect on target cells at a relatively low effector-to-target ratio. More importantly, we demonstrated that the antitumor activity of meso3-CD40CAR-T cells was enhanced in a human ovarian cancer xenograft model in vivo. CONCLUSIONS: In conclusion, these results highlight anti-CD40-secreting CAR-T cells generated by nonviral vectors as a potential clinical strategy for improving the efficacy of CAR-T cell therapies.
Authors: R H Vonderheide; J P Dutcher; J E Anderson; S G Eckhardt; K F Stephans; B Razvillas; S Garl; M D Butine; V P Perry; R J Armitage; R Ghalie; D A Caron; J G Gribben Journal: J Clin Oncol Date: 2001-07-01 Impact factor: 44.544
Authors: Bianca von Scheidt; Minyu Wang; Amanda J Oliver; Jack D Chan; Metta K Jana; Aesha I Ali; Fiona Clow; John D Fraser; Kylie M Quinn; Phillip K Darcy; Michael H Kershaw; Clare Y Slaney Journal: Proc Natl Acad Sci U S A Date: 2019-11-25 Impact factor: 11.205
Authors: Elise A Chong; J Joseph Melenhorst; Simon F Lacey; David E Ambrose; Vanessa Gonzalez; Bruce L Levine; Carl H June; Stephen J Schuster Journal: Blood Date: 2016-12-28 Impact factor: 22.113
Authors: Gregory L Beatty; Drew A Torigian; E Gabriela Chiorean; Babak Saboury; Alex Brothers; Abass Alavi; Andrea B Troxel; Weijing Sun; Ursina R Teitelbaum; Robert H Vonderheide; Peter J O'Dwyer Journal: Clin Cancer Res Date: 2013-08-27 Impact factor: 12.531
Authors: Andrea Franson; Brandon L McClellan; Maria Luisa Varela; Andrea Comba; Mohammad Faisal Syed; Kaushik Banerjee; Ziwen Zhu; Nazareno Gonzalez; Marianela Candolfi; Pedro Lowenstein; Maria Graciela Castro Journal: Front Med (Lausanne) Date: 2022-09-14